<unk>  is used as a second-line treatment to lower LDL cholesterol for adults who have a severe form of hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked. It is administered by subcutaneous injection. As of July 2015, it is not known whether<unk>  prevents early death from cardiovascular disease or prevents heart attacks; a clinical trial to determine outcomes was ongoing at that time, the results of which were expected in 2017. In November 2018, The New England Journal of Medicine published positive results from a clinical trial with<unk> . According to the study,<unk>  significantly reduced major adverse cardiovascular events by 15% and it was associated with a 15% lower risk of death from any cause (hazard ratio HR 0.85; 95% confidence interval CI, 0.73 to 0.98). In 2021, the U.S. Food and Drug Administration (FDA) added an indication for<unk>  to treat adults with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol. It is not intended to be used alone but instead added to other treatments for HoFH.
Alirocumab
Evolocumab
Olaratumab
Ustekinumab
Durvalumab
Emapalumab
Burosumab
Tralokinumab